drugset / Trial / NCT01552122
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral density in osteoporotic postmenopausal women who were previously treated with alendronate.
Timeline
- Start
- 2012-05
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alendronic Acid | Small molecule | 35 mg | Oral |
| Comparator | Alendronic Acid | Small molecule | 70 mg | Oral |
| Subject | Odanacatib | Small molecule | 50 mg | Oral |